1. Home
  2. BIOX vs TPST Comparison

BIOX vs TPST Comparison

Compare BIOX & TPST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Bioceres Crop Solutions Corp.

BIOX

Bioceres Crop Solutions Corp.

N/A

Current Price

$0.23

Market Cap

13.3M

Sector

Industrials

ML Signal

N/A

Logo Tempest Therapeutics Inc.

TPST

Tempest Therapeutics Inc.

N/A

Current Price

$0.38

Market Cap

13.7M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
BIOX
TPST
Founded
2001
2011
Country
Argentina
United States
Employees
N/A
N/A
Industry
Agricultural Chemicals
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
13.3M
13.7M
IPO Year
2019
2012

Fundamental Metrics

Financial Performance
Metric
BIOX
TPST
Price
$0.23
$0.38
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
★ 218.1K
124.1K
Earning Date
11-16-2026
11-17-2026
Dividend Yield
N/A
N/A
EPS Growth
★ N/A
N/A
EPS
★ N/A
N/A
Revenue
N/A
★ $295,000.00
Revenue This Year
$59.25
N/A
Revenue Next Year
$34.94
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
★ N/A
N/A
52 Week Low
$0.19
$0.46
52 Week High
$2.03
$10.33

Technical Indicators

Market Signals
Indicator
BIOX
TPST
Relative Strength Index (RSI) 41.13 21.87
Support Level $0.19 N/A
Resistance Level $0.55 $0.56
Average True Range (ATR) 0.04 0.05
MACD 0.00 -0.01
Stochastic Oscillator 47.57 3.65

Price Performance

Historical Comparison
BIOX
TPST

About BIOX Bioceres Crop Solutions Corp.

Bioceres Crop Solutions Corp is a fully integrated provider of crop productivity solutions, including seeds, seed traits, seed treatments, biologicals, high-value adjuvants, and fertilizers. The company has developed a multi-discipline and multi-product platform capable of providing solutions throughout the entire crop cycle, from pre-planting to transportation and storage. Some of the products offered by the company include fertilizers, inoculants, adjuvants, crop protection solutions, and seeds among others. Its operating segments are crop protection, which derives key revenue, seed and integrated products, and crop nutrition. Geographically, the majority of the company's revenue is generated from Argentina and the rest from Brazil, North America, Latin America, and other regions.

About TPST Tempest Therapeutics Inc.

Tempest Therapeutics Inc is a late-stage develpment biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity. Its clinical-stage therapeutic product candidates are TPST-1120 and TPST-1495 which are clinical-stage molecules designed to inhibit their respective targets. Company's small-molecule product candidate, amezalpat (previously known as TPST-1120), has completed a Phase 2 study in first-line hepatocellular carcinoma and the second small-molecule product candidate is TPST-1495, plans to initiate a Phase 2 study for in familial adenomatous polyposis.

Share on Social Networks: